NCT05590221View on ClinicalTrials.gov

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

February 10, 2024

Study Completion Date

December 10, 2024

Conditions
B-cell Lymphoma
Interventions
BIOLOGICAL

Relmacabtagene Autoleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Trial Locations (4)

100010

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Peking University International Hospital, Beijing

300060

NOT_YET_RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

450003

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
collaborator

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY

lead

Peking University Cancer Hospital & Institute

OTHER